NCHR supports the proposed FDA rule, which aims to reclassify wound dressings and liquid wound washes containing antimicrobials based on their level of antimicrobial resistance (AMR), with higher-risk products categorized as Class III. This change is crucial for mitigating the public health threat posed by AMR, ensuring the appropriate use of these medical devices, and ultimately improving patient outcomes.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Statement of Dr. Diana Zuckerman on Behalf of the National Center for Health Research FDA Advisory Committee Meeting on AMX0035 for ALS
September 7, 2022 Diana Zuckerman testified on behalf of NCHR at the FDA Advisory Committee hearing about the poor evidence foe Amylyx drug AMX0035 for the treatment of ALS, and how approving this drug would undermine other ALS clinical trials that are underway.
Read More »NCHR Testimony in Support of HB1147 for the Maryland House of Delegates Environment and Transportation Committee
February 28, 2024: NCHR provided written testimony to the Maryland House of Delegates Environment and Transportation Committee in support of HB1147, a bill to prohibit the sale and installation of playground surfaces that contain levels of lead, PFAS, or PAH chemicals.
Read More »NCHR Written Testimony in Support of HB457 for the Maryland House of Delegates Environment and Transportation Committee
February 16, 2024: NCHR provides written testimony to the Maryland House of Delegates Environment and Transportation Committee to support HB457, which requires transparency regarding all new artificial turf and infill installation, use, reuse, recycling, and disposal. This information would enable communities to make informed decisions about artificial turf that take into account how long it lasts and its impact on the environment.
Read More »NCHR Agrees with CDC Draft Recommendation to Remove Liraglutide and Pertuzumab from the National Institute for Occupational Safety and Health Hazardous Drugs in Healthcare Settings List
February 15th, 2024: NCHR supports the CDC recommendation to remove Liraglutide and Pertuzumab drugs from the NIOSH List of Hazardous Drugs in Healthcare Settings. We agree that due to the to the drugs’ low bioavailability and limited risk of occupational exposures these drugs are unlikely to pose a harm to healthcare workers.
Read More »